Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/23888
Başlık: Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women
Yazarlar: Kaya, Hakan
Özkaya, Okan
Sezik, Mekin
Arslanoğlu, Evrim
Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.
Yılmaztepe, Arzu
Ulukaya, Engin
K-5792-2018
8606136100
6602927353
Anahtar kelimeler: Geriatrics & gerontology
Obstetrics & gynecology
Raloxifene
Superoxide dismutase
Glutathione peroxidase
Malondialdehyde
Antioxidant
Estrogen-receptor modulator
Coronary-heart-disease
Nitric-oxide
Ovariectomized rats
Antioxidant enzymes
In-vitro
Replacement
Brain
Yayın Tarihi: 14-Mar-2005
Yayıncı: Elsevier
Atıf: Kaya, H. vd. (2005). "Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women". Maturitas, 50(3), 182-188.
Özet: Objective: To investigate the relationship between raloxifene administration and serum malondialdehyde (MDA), erythrocyte superoxide dismutase (SOD), erythrocyte glutathione peroxidase (GPx) levels in healthy postmenopausal women. Methods: In a randomized and placebo-controlled design, 80 women received either 60 mg/day raloxifene or placebo for 24 weeks. MDA, SOD, and GPx levels were assessed at 0,4,12, and 24 weeks. Wilcoxon signed-rank test and Mann-Whitney U test were used for comparisons. Results: Six women in the treatment arm and eight women in the placebo group discontinued the study. Mean serum MDA levels were significantly (p = 0.001) decreased from 11.4 nmol/ml at baseline to 8.9 nmol/ml at week 12 with raloxifene treatment. Mean erythrocyte SOD activity was significantly (p = 0.02) reduced from 1472 U/g Hb at baseline to 1173 U/g Hb at week 12 following raloxifene administration. Lowered serum MDA and erythrocyte SOD levels persisted during treatment. On contrary, erythrocyte GPx levels did not change significantly with raloxifene administration. Conclusions: Raloxifene (60 mg/day) lowers serum MDA levels and erythrocyte SOD activity in postmenopausal women after 12 weeks of treatment. The clinical implications of these findings need to be determined.
URI: https://doi.org/10.1016/j.maturitas.2004.05.005
https://www.sciencedirect.com/science/article/pii/S0378512204001744#!
https://www.maturitas.org/article/S0378-5122(04)00174-4/fulltext
http://hdl.handle.net/11452/23888
ISSN: 0378-5122
1873-4111
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Yılmaztepe_vd_2005.pdf113.72 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons